Stockscreener 앱 받기
26.43
0.83%
-0.22
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Arcutis To Present At Guggenheim Emerging Outlook Biotech Summit; Report Q4 Results In Feb - RTTNews
Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference - The Manila Times
Arcutis Biotherapeutics : to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Invest - marketscreener.com
Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference - GlobeNewswire Inc.
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions - markets.businessinsider.com
Arcutis Biotherapeutics (ARQT) Reveals Insights on Steroid Use i - GuruFocus
Why 9 in 10 patients on steroid creams fear their skin treatment - Stock Titan
Published on: 2026-01-17 08:06:24 - baoquankhu1.vn
Is Arcutis Biotherapeutics Inc stock undervalued right nowMarket Weekly Review & Weekly Top Gainers Trade List - baoquankhu1.vn
Price-Driven Insight from (ARQT) for Rule-Based Strategy - Stock Traders Daily
Market Moves: Is Arcutis Biotherapeutics Inc stock good for income investorsPortfolio Update Report & Community Driven Trade Alerts - baoquankhu1.vn
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Unloaded Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT): Investor Outlook Reveals 18% Upside Potential - DirectorsTalk Interviews
Arcutis Biotherapeutics: Strengthening Zoryve Franchise, Approaching Profitability, and Multiple 2026+ Pipeline Catalysts Support Buy Rating - TipRanks
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 7.3%Here's What Happened - MarketBeat
Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus - TechStock²
Arcutis highlights 2026 strategic priorities and anticipated milestones - marketscreener.com
Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones - The Manila Times
Skin drug maker maps 2026 plans, from infant trials to $470M sales - Stock Titan
Risk Recap: Is Arcutis Biotherapeutics Inc. stock a buy before product launchesMarket Movers & Fast Gaining Stock Reports - ulpravda.ru
Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings - TechStock²
Earnings Report: Will Arcutis Biotherapeutics Inc. stock beat EPS estimatesJuly 2025 Rallies & Reliable Entry Point Trade Alerts - Улправда
How Arcutis Biotherapeutics Inc. stock compares to growth peersEarnings Overview Summary & Weekly Chart Analysis and Guides - ulpravda.ru
Is Arcutis Biotherapeutics Inc. stock a buy before product launchesMarket Movers & Fast Gaining Stock Reports - ulpravda.ru
Patrick Burnett Sells 2,490 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Arcutis Bio EVP Burnett sells $72k in shares By Investing.com - Investing.com Canada
Arcutis Bio EVP Burnett sells $72k in shares - Investing.com
Arcutis Biotherapeutics, Inc.Common stock (NQ: ARQT - FinancialContent
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: Revenue Surge and Analyst Consensus Signal Opportunity - DirectorsTalk Interviews
Arcutis BiotherapeuticsFocusing On ZORYVE Market Expansion And Pipeline Growth - RTTNews
(ARQT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arcutis Biotherapeutics (NASDAQ:ARQT) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Arcutis Biotherapeutics CEO Todd Watanabe sells $245,122 in shares - MSN
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $49,552.40 in Stock - MarketBeat
Arcutis Biotherapeutics EVP Burnett sells $49,560 in shares By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics EVP Burnett sells $49,560 in shares - Investing.com
Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates - TechStock²
Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day - ts2.tech
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 3.4%Still a Buy? - MarketBeat
Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade - ts2.tech
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Rating Lowered by Zacks Research - MarketBeat
Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3% - ts2.tech
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: A 10.73% Potential Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews
Arcutis Biotherapeutics, Inc. $ARQT Shares Sold by Simplify Asset Management Inc. - MarketBeat
Arcutis Biotherapeutics Earnings Notes - Trefis
Arcutis Biotherapeutics (NASDAQ:ARQT) Downgraded by Wall Street Zen to Buy - MarketBeat
Is Suvretta’s Stake Cut and FDA’s Pediatric Review Acceptance Altering The Investment Case For Arcutis Biotherapeutics (ARQT)? - Yahoo Finance
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - Yahoo Finance
4.07%
1.75%
자본화:
|
볼륨(24시간):